A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
Abstract Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic com...
Guardado en:
Autores principales: | Yong Cheng, Qingyu Meng, Dandan Linghu, Mingwei Zhao, Jianhong Liang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a6976448096415bb298f7741443f4aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
por: Majid Abrishami, et al.
Publicado: (2021) -
Clinical therapeutic effects of intravitreal injection of Conbercept for macular edema in different types of retinal vein occlusion
por: Peng-Yao Lin, et al.
Publicado: (2021) -
A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits
por: Jiaming Wang, et al.
Publicado: (2017) -
Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
por: Obata S, et al.
Publicado: (2019) -
Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo O, et al.
Publicado: (2015)